Zuriah A. Meacham

Abstract Treating human genetic conditions in vivo requires efficient delivery of the CRISPR gene editing machinery to the affected cells and organs. The gene editing field has seen clinical advances with ex vivo therapies and with in vivo delivery to the liver using lipid nanoparticle technology. Adeno-associated virus (AAV) serotypes have been discovered and engineered to deliver genetic material to nearly every organ in the body.

Loading metrics Open Access Peer-reviewed Discovery Report Discovery Reports capture exploratory initial findings centered around a valuable and interesting research question. See all article types » ? This is an uncorrected proof. Citation: Meacham Z, de Tacca LA, Bondy-Denomy J, Rabuka D, Schelle M (2023) Cas9 degradation in human cells using phage anti-CRISPR proteins. PLoS Biol 21(12): e3002431. https://doi.org/10.1371/journal.pbio.3002431 Academic Editor: Franklin L.

Abstract The precision of gene editing technology is critical to creating safe and effective therapies for treating human disease. While the programmability of CRISPR-Cas systems has allowed for rapid innovation of new gene editing techniques, the off-target activity of these enzymes has hampered clinical development for novel therapeutics. Here we report the identification and characterization of a novel CRISPR-Cas12a enzyme from Acinetobacter indicus (AiCas12a).